China’s vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing.<\/p>\n
China confirmed its first COVID-19 vaccine patent Sunday, according to state-affiliated media.<\/p>\n
“#China has approved its first #COVID19 #vaccine patent, which has been developed by PLA infectious disease expert Chen Wei’s team. Earlier, the phase 2 trial of the vaccine candidate found that the vaccine is safe and induces an immune response,” China Global Television Network (CGTN) said on Twitter.<\/p>\n
Citing data from clinical trials published in the Journal of the American Medical Association, China’s state-run Xinhua News Agency reported earlier in the day that the COVID-19 vaccine candidate is “safe and generates an immune response.”<\/p>\n
The research involved 320 “healthy volunteers” aged between 18 and 59, of which 96 participated in phase-1 clinical trials and 224 in phase-2 trials, it said.<\/p>\n
Xinhua said the results indicated that the vaccine effectively induced neutralizing antibodies in the volunteers and demonstrated good ability of a substance to trigger an immune response.<\/p>\n
On Saturday, Russia\u2019s Health Ministry announced that the country has started production of its first COVID-19 vaccine, noting initial batches will be earmarked for immunizing doctors and health workers before going to the general public.<\/p>\n
Russia officially registered the world\u2019s first coronavirus vaccine, developed by the Gamaleya Research Institute of Epidemiology and Microbiology, on Tuesday.<\/p>\n
The announcement drew skepticism worldwide as Russia plans to continue a third phase of trials along with the vaccine\u2019s production and use.<\/p>\n","protected":false},"excerpt":{"rendered":"
China’s vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing. China confirmed its first COVID-19 vaccine patent Sunday, according to state-affiliated media. “#China has approved its first #COVID19 #vaccine patent, which has been developed by PLA infectious disease expert Chen Wei’s team. Earlier, the phase 2 trial of the vaccine candidate found …<\/p>\n","protected":false},"author":3,"featured_media":66416,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[107],"tags":[2381,78536],"class_list":["post-66415","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-china","tag-corona-virus"],"_links":{"self":[{"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/posts\/66415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/comments?post=66415"}],"version-history":[{"count":0,"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/posts\/66415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/media\/66416"}],"wp:attachment":[{"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/media?parent=66415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/categories?post=66415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationalturk.com\/en\/wp-json\/wp\/v2\/tags?post=66415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}